echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > First-in-class immunomodulators are reacquired to fda fast-track for the treatment of scleroderma-related interstitial lung disease

    First-in-class immunomodulators are reacquired to fda fast-track for the treatment of scleroderma-related interstitial lung disease

    • Last Update: 2022-09-20
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On September 14, aTyr Pharma announced that the U.


    Systemic sclerosis is a chronic progressive autoimmune disease characterized by inflammation and fibrosis of connective tissue throughout the body, including the skin and other internal organs


    The pathogenesis of SSc-ILD is driven by the same immune cells that play a central role in the pathology of pulmonary sarcoidosis, and neuroprotin-2 (NRP2) on these cells is upregulated


    In animal models of SSc and idiopathic pulmonary fibrosis, efzofitimod has been shown to reduce lung and skin fibrosis, with efficacy comparable to or better than known antifibrosis drugs, including nidanibu and pirfenidone


    The main indication developed by aTyr for efzofitimod is pulmonary sarcoidosis, a major type


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.